Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07003919 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
A Phase 3 study of Allergy and Peanut Allergy, sponsored by DBV Technologies.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT07003919: Recruiting Phase 3 study of Allergy and Peanut Allergy, sponsored by DBV Technologies.
NCT07003919 is a Phase 3 study of Allergy and Peanut Allergy that is actively recruiting participants, run by DBV Technologies. The registered enrollment target is 480 participants, above the 300-participant average among 15 other Allergy trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07003919, a Phase 3 study of Allergy and Peanut Allergy, is actively recruiting participants, sponsored by DBV Technologies.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT DBV712 250 mcg
Study Locations (20)
California
- Modena Allergy & Asthma - La Jolla
- Modena Allergy and Asthma - Long Beach
- UCLA Health Westwood Pediatrics - Los Angeles
- Children's Hospital of Los Angeles - Los Angeles
- Allergy & Asthma Associates of Southern California - Mission Viejo
- Lucile Packard Children's Hospital Stanford - Palo Alto
- Allergy & Asthma Medical Group and Research Center - San Diego
- Rady Children's Hospital - San Diego - San Diego
- Orso Health Torrance - Torrance
Alabama
- AllerVie Clinical Research - Birmingham
- University of Alabama at Birmingham Pediatric Primary Care Clinic - Birmingham
Arizona
- Modena Allergy & Asthma - Scottsdale
- University of Arizona Asthma and Airway Disease Research Center - Tucson
Colorado
- Children's Hospital Colorado - Aurora
- Asthma & Allergy Associates - Colorado Springs
Florida
- University of South Florida Children's Research Institute - St. Petersburg
- Allergy, Asthma & Immunology Associates of Tampa Bay - Tampa
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Children's National - Main Hospital - Washington D.C.
Georgia
- Emory University - Children's Healthcare of Atlanta, Inc. - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT07003919 shows while recruiting
NCT07003919 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 300-participant average among 15 other Allergy trials with a reported enrollment target (60% higher).
The record links to 2 conditions, with Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07003919 names 20 study sites across 8 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07003919 about?
NCT07003919 is a clinical study titled "Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)". The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
What is the current status of trial NCT07003919?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-06-24. Estimated completion is 2028-05.
What conditions does trial NCT07003919 study?
This clinical trial studies the following conditions: Allergy, Peanut Allergy.
What interventions are being tested in trial NCT07003919?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), DBV712 250 mcg (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07003919?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07003919 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07003919's enrollment target sits among peer trials
480 4th of 15 higher than 12 of 15 other Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
RECRUITING · Phase 4
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
-
Urban Environmental Factors and Childhood Asthma
COMPLETED
-
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
COMPLETED · Phase 2
-
Vitamin D, Steroids, and Asthma in African American Youth
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI